AAPL   268.89 (+1.25%)
FB   200.74 (+0.69%)
MSFT   150.66 (+0.49%)
GOOGL   1,341.63 (+1.72%)
AMZN   1,753.29 (-0.42%)
CGC   18.61 (+0.05%)
NVDA   213.14 (+1.78%)
GE   10.97 (+1.67%)
TSLA   336.87 (+1.15%)
T   38.43 (+0.63%)
AMD   40.08 (+0.98%)
PRI   136.21 (+1.42%)
BAC   33.65 (+1.69%)
DIS   148.27 (+0.56%)
AAPL   268.89 (+1.25%)
FB   200.74 (+0.69%)
MSFT   150.66 (+0.49%)
GOOGL   1,341.63 (+1.72%)
AMZN   1,753.29 (-0.42%)
CGC   18.61 (+0.05%)
NVDA   213.14 (+1.78%)
GE   10.97 (+1.67%)
TSLA   336.87 (+1.15%)
T   38.43 (+0.63%)
AMD   40.08 (+0.98%)
PRI   136.21 (+1.42%)
BAC   33.65 (+1.69%)
DIS   148.27 (+0.56%)
AAPL   268.89 (+1.25%)
FB   200.74 (+0.69%)
MSFT   150.66 (+0.49%)
GOOGL   1,341.63 (+1.72%)
AMZN   1,753.29 (-0.42%)
CGC   18.61 (+0.05%)
NVDA   213.14 (+1.78%)
GE   10.97 (+1.67%)
TSLA   336.87 (+1.15%)
T   38.43 (+0.63%)
AMD   40.08 (+0.98%)
PRI   136.21 (+1.42%)
BAC   33.65 (+1.69%)
DIS   148.27 (+0.56%)
AAPL   268.89 (+1.25%)
FB   200.74 (+0.69%)
MSFT   150.66 (+0.49%)
GOOGL   1,341.63 (+1.72%)
AMZN   1,753.29 (-0.42%)
CGC   18.61 (+0.05%)
NVDA   213.14 (+1.78%)
GE   10.97 (+1.67%)
TSLA   336.87 (+1.15%)
T   38.43 (+0.63%)
AMD   40.08 (+0.98%)
PRI   136.21 (+1.42%)
BAC   33.65 (+1.69%)
DIS   148.27 (+0.56%)
Log in

NASDAQ:ALEC - Alector Stock Price, Forecast & News

$20.00
+0.61 (+3.15 %)
(As of 12/6/2019 10:06 AM ET)
Today's Range
$19.52
Now: $20.00
$20.12
50-Day Range
$14.33
MA: $16.65
$19.51
52-Week Range
$13.64
Now: $20.00
$27.00
Volume73,523 shs
Average Volume298,075 shs
Market Capitalization$1.38 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Alector, Inc., a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease. The company's preclinical stage products comprise AL101 for the treatment of multiple neurodegenerative disorders; and AL003 for the treatment of Alzheimer's disease. It also has 10 programs under research and development stage. The company was founded in 2013 and is headquartered in South San Francisco, California.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALEC
CUSIPN/A
CIKN/A
Phone415-231-5660

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$27.51 million

Profitability

Net Income$-52,250,000.00
Net Margins-378.57%

Miscellaneous

Employees91
Market Cap$1.38 billion
Next Earnings Date3/24/2020 (Estimated)
OptionableNot Optionable

Receive ALEC News and Ratings via Email

Sign-up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter.


Alector (NASDAQ:ALEC) Frequently Asked Questions

What is Alector's stock symbol?

Alector trades on the NASDAQ under the ticker symbol "ALEC."

How were Alector's earnings last quarter?

Alector Inc (NASDAQ:ALEC) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.47) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.40) by $0.07. The business had revenue of $2.70 million for the quarter. Alector had a negative return on equity of 58.27% and a negative net margin of 378.57%. View Alector's Earnings History.

When is Alector's next earnings date?

Alector is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for Alector.

What price target have analysts set for ALEC?

7 equities research analysts have issued 12 month target prices for Alector's shares. Their forecasts range from $26.00 to $28.00. On average, they anticipate Alector's share price to reach $27.00 in the next year. This suggests a possible upside of 35.1% from the stock's current price. View Analyst Price Targets for Alector.

What is the consensus analysts' recommendation for Alector?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alector.

Has Alector been receiving favorable news coverage?

News articles about ALEC stock have been trending somewhat negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Alector earned a news impact score of -1.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Alector.

Are investors shorting Alector?

Alector saw a drop in short interest during the month of October. As of October 15th, there was short interest totalling 4,670,000 shares, a drop of 15.6% from the September 15th total of 5,530,000 shares. Based on an average trading volume of 391,700 shares, the short-interest ratio is currently 11.9 days. Approximately 11.6% of the shares of the company are short sold. View Alector's Current Options Chain.

Who are some of Alector's key competitors?

What other stocks do shareholders of Alector own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Cisco Systems (CSCO), Alibaba Group (BABA), Editas Medicine (EDIT), NVIDIA (NVDA), CVS Health (CVS), Johnson & Johnson (JNJ), Verizon Communications (VZ), Home Depot (HD), Honeywell International (HON) and Amgen (AMGN).

Who are Alector's key executives?

Alector's management team includes the folowing people:
  • Dr. Tillman U. Gerngross, Co-Founder & Chairman (Age 55)
  • Dr. Arnon Rosenthal, Co-Founder, CEO, Pres & Director (Age 64)
  • Dr. Robert Paul M.D., Ph.D., Chief Medical Officer (Age 51)
  • Dr. Robert S. King, Chief Devel. Officer (Age 56)
  • Dr. Asa Abeliovich M.D., Ph.D., Co-Founder

When did Alector IPO?

(ALEC) raised $177 million in an IPO on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO.

Who are Alector's major shareholders?

Alector's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Orbimed Advisors LLC (18.18%), State Street Corp (0.69%), Millennium Management LLC (0.47%), Mascoma Wealth Management LLC (0.27%), Oppenheimer & Co. Inc. (0.09%) and Russell Investments Group Ltd. (0.09%). Company insiders that own Alector stock include Calvin Yu, Orbimed Advisors Llc, Robert King and Robert Paul. View Institutional Ownership Trends for Alector.

Which major investors are selling Alector stock?

ALEC stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC. Company insiders that have sold Alector company stock in the last year include Calvin Yu, Orbimed Advisors Llc, Robert King and Robert Paul. View Insider Buying and Selling for Alector.

Which major investors are buying Alector stock?

ALEC stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Mascoma Wealth Management LLC, Millennium Management LLC, Russell Investments Group Ltd., California State Teachers Retirement System, Rhumbline Advisers, Voya Investment Management LLC and Barclays PLC. View Insider Buying and Selling for Alector.

How do I buy shares of Alector?

Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Alector's stock price today?

One share of ALEC stock can currently be purchased for approximately $19.98.

How big of a company is Alector?

Alector has a market capitalization of $1.38 billion and generates $27.51 million in revenue each year. The company earns $-52,250,000.00 in net income (profit) each year or ($4.62) on an earnings per share basis. Alector employs 91 workers across the globe.View Additional Information About Alector.

What is Alector's official website?

The official website for Alector is http://www.alector.com/.

How can I contact Alector?

Alector's mailing address is 151 OYSTER POINT BLVD. SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-231-5660 or via email at [email protected]


MarketBeat Community Rating for Alector (NASDAQ ALEC)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  84 (Vote Outperform)
Underperform Votes:  89 (Vote Underperform)
Total Votes:  173
MarketBeat's community ratings are surveys of what our community members think about Alector and other stocks. Vote "Outperform" if you believe ALEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALEC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel